English
miR Sentinel’s accuracy and accessibility in diagnosing and classifying prostate cancer can meaningfully alleviate the economic and human burden of one of the world’s most prevalent and deadly diseases.
Our miR Sentinel™ Test uses precise biologic information interrogation techniques to categorize patients into one of four groups: no molecular evidence of prostate cancer, low-risk cancer, intermediate-risk cancer, or elevated risk cancer. This helps physicians determine which patients need treatment and which can be monitored, helping avoid harmful and costly over-treatment. Our highly accurate, easy-to-administer urine test is powered by our algorithm-based miR Disease Management Platform™ designed to help physicians diagnose and monitor patients across the continuum of cancer care for optimal case management and prioritization.
.png)
Our miR SentinelTM Prostate Cancer Test uses precise biologic information interrogation techniques to categorize patients into one of four groups: no molecular evidence of prostate cancer, low-risk cancer, moderate-risk cancer, or elevated-risk cancer.
This helps physicians determine which patients need treatment and which can be monitored, helping avoid harmful and costly overtreatment.
Our highly accurate, easy-to-administer urine test is powered by our algorithm-based miR Disease Management Platform® designed to help physicians diagnose and monitor patients across the continuum of cancer care for optimal case management and prioritization.
miR is the only prostate cancer test that provides an accurate measure of molecular malignancy to answer the most critical cancer questions. When it comes to cancer, we provide answers, not more questions.
Outperform today’s standard of care and decrease the invasiveness for your patients. Our results will transform the standard of urologic oncology care with highly accurate, easily administered, and cost-effective end-to-end cancer management tools that reduce poor outcomes and eliminate waste.
The miR disease management platform delivers clarity and peace of mind to all involved in prostate cancer care from diagnosis through disease management:
Our non-invasive, pain-free prostate cancer diagnostic testing and monitoring platform helps physicians, patients, and payors realize true cost-effectiveness and efficiency in prostate cancer screening and management for the first time.
Leverage the most accurate prostate cancer decision-making platform to identify and rapidly treat patients with the greatest need.
Experience a non-invasive, accurate, accessible prostate cancer test that delivers clear results to you and your doctor with a single urine specimen.
Leverage the most accurate prostate cancer decision-making platform to identify and rapidly treat patients with the greatest need.
One urine sample is all that’s required to accurately detect and classify prostate cancer. Our miR Disease Management Platform® is not reliant on clinical risk factors such as age, PSA, or histopathology, and can detect sncRNA from small, potentially aggressive tumors that can be missed by TRUS or MRI-guided biopsies and/or not recorded on pathology.
In addition to being invasive and potentially leading to impotence, incontinence, infection and over-treatment, the PSA test and biopsy combination has just a 44% Sensitivity level—making it highly inaccurate and necessary to repeat often.
Although elevated PSA levels can be an indicator of the presence of prostate cancer, many other factors not related to cancer can return an elevated PSA test.
Avoid the inaccurate, often unnecessary PSA test–rectal exam–biopsy cycle and get real answers fast. miR provides industry-low false-positive and false-negative rates for maximum confidence in clinical pathways.
miR delivers accurate diagnosis and classification results using highly accurate molecular RNA interrogation and sophisticated algorithms based on hundreds of biomarkers.
The prostate-specific antigen (PSA) test is a blood test that healthcare providers use as a screen for prostate cancer. If the PSA test results are “elevated,” your provider may recommend a prostate biopsy to better understand if you have cancer or not.
There is no standard cut-point to define an “elevated” PSA result. The AUA guidelines state that varying protocols have been used, including PSA thresholds as low as 3.0 ng/mL and as high as 10 ng/mL. The National Comprehensive Cancer Network (NCCN) recommends a PSA test at least every 6 months, digital rectal exams every year, and a repeat biopsy within 18 months of diagnosis.
.png)
